Macrogen Licenses Gene Editing Technology from Broad Institute of MIT and Harvard in the USA – CRISPR-Cas9 commercial research tool technology acquired from Broad Institute will be used to build preclinical model animals and target treatment function analysis to further gene treatment research and development SEOUL, South Korea–Macrogen, Inc. (CEO Ji-young Moon, www.macrogen.com) (KOSDAQ: 038290), a precision medicinebiotechnology company, … Continue reading Macrogen Licenses Gene Editing Technology from Broad Institute of MIT and Harvard in the USA